206 results
40-F
2004 FY
EX-3
BLU
Bellus Health Inc
13 May 04
Annual report (Canada)
12:00am
and treat AD.
Funding
Since inception in 1993, Neurochem has devoted its resources principally to
funding research and development programs … . As at December 31, 2003, the Company
has incurred a cumulative deficit since inception of $86,365,000, of which
research and development expenditures totaled
40-F
2006 FY
EX-99.3
BLU
Bellus Health Inc
2 Mar 07
Annual report (Canada)
12:00am
:
Collaboration agreement
Reimbursable costs
Expenses:
Research and development (R&D)
Research tax credits and grants
Other R&D charges
General … costs.
Research and development expenses, before research tax credits and grants, amounted to $58,624,000 for the year ended December 31, 2006
6-K
EX-99.1
BLU
Bellus Health Inc
14 May 20
Condensed Consolidated Interim Financial Statements of
5:12pm
Total current assets
Non-current assets:
Right-of-use asset (note 5)
Other assets
In-process research and development asset (note 6)
Total non-current … -term investments
Purchases of short-term investments
Acquisition of in-process research and development asset, total contribution
paid and transaction
6-K
EX-99.2
BLU
Bellus Health Inc
10 May 21
Condensed Consolidated Interim Financial Statements of
4:48pm
conditions;
our expectations with respect to the timing and cost of the research and development activities of BLU-5937;
the function, potential benefits … of current research and development activities;
achievement of development and commercial milestones, including forecasted preclinical study
6-K
BLU
Bellus Health Inc
22 Feb 07
Current report (foreign)
12:00am
to $72,366,000 ($2.06 per share) for the same period in the previous year. Research and development (R&D) expenses increased during the fourth quarter … on these reimbursable costs.
Research and development expenses, before research tax credits and grants, amounted to $16,095,000 for the current quarter
F-10
EX-4.6
c0wbfrdu7yog r1
3 Sep 19
Registration of securities (Canada)
7:53am
40-F
EX-99.2
9r6hwrx
23 Feb 22
Annual report (Canada)
5:20pm
6-K
EX-99.1
2oobimw
13 Aug 20
Condensed Consolidated Interim Financial Statements of
4:01pm
F-10
EX-4.3
6wqkpoauq
3 Sep 19
Registration of securities (Canada)
7:53am
40-F
EX-99.3
ecz30bw
14 Mar 08
Annual report (Canada)
12:00am
6-K
EX-99.2
4di ss3kx
13 Aug 20
Condensed Consolidated Interim Financial Statements of
4:01pm
6-K
siyelwjnt9d9ull0iie1
24 Feb 06
Current report (foreign)
12:00am
40-F
EX-99.2
xvylrax937f37ire6n3
27 Feb 20
Annual report (Canada)
5:13pm
6-K
jha8lhju4hkv4kdfa1zl
7 Mar 06
Current report (foreign)
12:00am
6-K
EX-99.1
zsxujg2 nfdmsrv4
10 May 21
Condensed Consolidated Interim Financial Statements of
4:48pm
6-K
EX-99.1
g4n80yw7 y7
14 Nov 22
BELLUS Health Reports Third Quarter 2022 Financial Results and Business Highlights
4:03pm
6-K
EX-99.2
i40lv rrwl20qwlj
11 May 22
Condensed Consolidated Interim Financial Statements of
5:05pm
F-10
EX-4.3
8ikyb5y7ydk1
20 Dec 19
Registration of securities (Canada)
4:03pm
6-K
EX-99.1
lue xleerv
11 May 22
BELLUS Health Reports First Quarter 2022 Financial Results and Business Highlights
5:23pm
40-F
EX-99.2
j1rt2r2s5
25 Feb 21
Annual report (Canada)
4:58pm